Madrigal Pharmaceuticals Inc

MDGL

Company Profile

  • Business description

    Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

  • Contact

    200 Barr Harbor Drive
    Suite 200, Four Tower Bridge
    West ConshohockenPA19428
    USA

    T: +1 267 824-2827

    E: [email protected]

    https://www.madrigalpharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    528

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,820.306.40-0.07%
CAC 407,830.3371.92-0.91%
DAX 4024,230.82225.99-0.92%
Dow JONES (US)44,650.64192.340.43%
FTSE 1008,928.7146.95-0.52%
HKSE24,139.57111.200.46%
NASDAQ20,630.6619.330.09%
Nikkei 22539,569.6876.68-0.19%
NZX 50 Index12,686.6873.52-0.58%
S&P 5006,280.4617.200.27%
S&P/ASX 2008,580.109.10-0.11%
SSE Composite Index3,510.180.500.01%

Market Movers